About The Journal Open Access
Immunology is the examination of the resistant structure and is a fundamental piece of the clinical and natural sciences. The immune structure shields us from defilement through various lines of security. Case reports are considered if they are truly original and are accompanied by a succinct review of the relevant medical literature
Immunology Case Reports is a Peer reviewed medical journal that includes a wide range of fields in its discipline to create a platform for the authors to make their contributions towards the journal. Immunology case report is one of the longest-established immunology journals and is recognized as one of the leading journals in its field. We have global representation in authors, editors and reviewers
Open access is a bundle of principles and an extent of practices through which assessment yields are coursed on the web, liberated from access charges or various obstructions and average article publication time (5-7 days)
Immunology Case Reports is the unique platform for discussion that covers the topics such as Affinity maturation, Allergens, Cytokine, Mast cell, mutant reverse transcriptase, Plasma cell, Secondary immune response, Secondary lymphoid organs, and T cytotoxic cell.
Immunology Case Reports that aims to publish the most complete and reliable source of information on discoveries and current developments in the field as Research articles, Review articles, Case reports, Short communications, Editorial note, Short commentary, Image article, Mini review, Opinion, and Special issue.
You may submit manuscripts online at https://www.scholarscentral.org/submissions/immunology-case-reports.html or through mail at Immunology@emedicinejournals.org and We are Request you to Send manuscript and also join as an editorial board member.
Fast Editorial Execution and Review Process (FEE-Review Process):
The Journal of Immunology and Case Reports is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.
Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.
The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.
h-index
Articles published in Immunology Case Reports have been cited by esteemed scholars and scientists all around the world. Immunology Case Reports has got h-index 2 , which means every article in Immunology Case Reports has got 2 average citations.
editorialservice@alliedacademies.org
Just Published Articles View More
Short Communication August 31, 2023
P.1-2
Immune Syst Disord J: 6(4): 1-2
Secretome-based acellular therapy in degenerative and immunological disorders
Satyaraj Maggidi
DOI:
Short Communication August 31, 2023
P.1-2
Immune Syst Disord J: 6(4): 1-2
Unveiling the immunogenicity of low and high doses of fmp013
Asif Ahmed
DOI:
Mini Review August 31, 2023
P.1-2
Immune Syst Disord J: 6(4): 1-2
Immune and inflammatory responses in cancer and brain stem cells
Marsh Casino
DOI:
Perspective August 31, 2023
P.1-2
Immune Syst Disord J: 6(4): 1-2
Natural immunogenic I-Ab-restricted antigen human immune system
Daniel Bug
DOI:
Opinion Article August 31, 2023
P.1-2
Immune Syst Disord J: 6(4): 1-2
Immune checkpoint inhibitors (ICIs) in cancer immunotherapy
Abdul Reza
DOI:
Perspective August 31, 2023
P.1-2
Immune Syst Disord J: 6(4): 1-2
Gene Regulation in Innate and Adaptive Immune Cells
Xiaoyan Zhang
DOI: